Celldex Therapeutics Inc (CLDX) concluded trading on Thursday at a closing price of $18.30, with 0.46 million shares of worth about $8.38 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -37.76% during that period and on April 17, 2025 the price saw a gain of about 2.81%. Currently the company’s common shares owned by public are about 66.37M shares, out of which, 64.70M shares are available for trading.
Stock saw a price change of 14.81% in past 5 days and over the past one month there was a price change of -8.27%. Year-to-date (YTD), CLDX shares are showing a performance of -27.58% which decreased to -52.59% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $14.40 but also hit the highest price of $47.00 during that period. The average intraday trading volume for Celldex Therapeutics Inc shares is 821.21K. The stock is currently trading 2.33% above its 20-day simple moving average (SMA20), while that difference is down -7.90% for SMA50 and it goes to -35.77% lower than SMA200.
Celldex Therapeutics Inc (NASDAQ: CLDX) currently have 66.37M outstanding shares and institutions hold larger chunk of about 114.74% of that.
The stock has a current market capitalization of $1.21B and its 3Y-monthly beta is at 1.41. It has posted earnings per share of -$2.45 in the same period. It has Quick Ratio of 18.91 while making debt-to-equity ratio of 0.01. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CLDX, volatility over the week remained 5.76% while standing at 7.20% over the month.
Stock’s fiscal year EPS is expected to drop by -33.83% while it is estimated to decrease by -19.87% in next year. EPS is likely to shrink at an annualized rate of -15.12% for next 5-years, compared to annual growth of 6.91% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Morgan Stanley on March 20, 2025 offering an Overweight rating for the stock and assigned a target price of $46 to it. Coverage by UBS stated Celldex Therapeutics Inc (CLDX) stock as a Buy in their note to investors on February 13, 2025, suggesting a price target of $44 for the stock. On October 07, 2024, Citigroup Initiated their recommendations, while on September 30, 2024, Goldman Initiated their ratings for the stock with a price target of $45. Stock get a Peer perform rating from Wolfe Research on September 27, 2024.
